American Century Companies Inc. Grows Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

American Century Companies Inc. increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 13.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,468 shares of the biopharmaceutical company’s stock after purchasing an additional 6,955 shares during the quarter. American Century Companies Inc.’s holdings in Royalty Pharma were worth $1,595,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc increased its holdings in Royalty Pharma by 5,215.0% in the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,043 shares during the last quarter. Gladius Capital Management LP purchased a new position in shares of Royalty Pharma in the 2nd quarter valued at about $32,000. Fidelis Capital Partners LLC acquired a new stake in shares of Royalty Pharma during the 1st quarter worth about $46,000. GAMMA Investing LLC lifted its stake in Royalty Pharma by 172.5% during the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,037 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Royalty Pharma by 62.7% in the fourth quarter. Parallel Advisors LLC now owns 2,882 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 1,111 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX opened at $28.21 on Monday. Royalty Pharma plc has a 52-week low of $25.20 and a 52-week high of $31.66. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The firm has a 50-day moving average price of $28.01 and a 200 day moving average price of $27.90. The firm has a market capitalization of $16.74 billion, a PE ratio of 21.05, a P/E/G ratio of 4.09 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The company had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period last year, the business earned $0.85 EPS. On average, sell-side analysts anticipate that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date of this dividend was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Morgan Stanley lifted their target price on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. UBS Group downgraded shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research report on Monday, June 3rd. The Goldman Sachs Group increased their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.